JPH026328B2 - - Google Patents
Info
- Publication number
- JPH026328B2 JPH026328B2 JP10620382A JP10620382A JPH026328B2 JP H026328 B2 JPH026328 B2 JP H026328B2 JP 10620382 A JP10620382 A JP 10620382A JP 10620382 A JP10620382 A JP 10620382A JP H026328 B2 JPH026328 B2 JP H026328B2
- Authority
- JP
- Japan
- Prior art keywords
- background background
- animals
- humans
- infections
- present
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000003814 drug Substances 0.000 claims description 24
- 241001465754 Metazoa Species 0.000 claims description 16
- 201000010099 disease Diseases 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000035473 Communicable disease Diseases 0.000 claims description 12
- 208000026278 immune system disease Diseases 0.000 claims description 10
- 230000003449 preventive effect Effects 0.000 claims description 9
- 229940124597 therapeutic agent Drugs 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 6
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 3
- 229920001550 polyprenyl Polymers 0.000 claims description 3
- 125000001185 polyprenyl group Polymers 0.000 claims description 3
- 150000002576 ketones Chemical class 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 description 19
- 208000015181 infectious disease Diseases 0.000 description 19
- 229940079593 drug Drugs 0.000 description 15
- 241000282412 Homo Species 0.000 description 9
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 239000000843 powder Substances 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- -1 ketone compounds Chemical class 0.000 description 7
- 244000144972 livestock Species 0.000 description 7
- 239000000203 mixture Substances 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 229920002261 Corn starch Polymers 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000007796 conventional method Methods 0.000 description 6
- 239000008120 corn starch Substances 0.000 description 6
- 229940099112 cornstarch Drugs 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 5
- 206010035664 Pneumonia Diseases 0.000 description 5
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 238000002347 injection Methods 0.000 description 5
- 239000007924 injection Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 5
- 239000008108 microcrystalline cellulose Substances 0.000 description 5
- 229940016286 microcrystalline cellulose Drugs 0.000 description 5
- 208000035143 Bacterial infection Diseases 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000022362 bacterial infectious disease Diseases 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 230000007123 defense Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- 206010057249 Phagocytosis Diseases 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 230000036737 immune function Effects 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 244000144977 poultry Species 0.000 description 3
- 235000013594 poultry meat Nutrition 0.000 description 3
- 230000000069 prophylactic effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 2
- 241000606790 Haemophilus Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 229940084030 carboxymethylcellulose calcium Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 235000011121 sodium hydroxide Nutrition 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- OJADOGDELNTUGN-UHFFFAOYSA-N (all-E)-6,10,14,18,22,26,30-heptamethyl-hentriaconta-5,9,13,17,21,25,29-heptaen-2-one Natural products CC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=CCCC(C)=O OJADOGDELNTUGN-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000588722 Escherichia Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 241000581650 Ivesia Species 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 241000606860 Pasteurella Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000009470 Theobroma cacao Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 159000000032 aromatic acids Chemical class 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000009833 condensation Methods 0.000 description 1
- 230000005494 condensation Effects 0.000 description 1
- 239000007859 condensation product Substances 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 238000006114 decarboxylation reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007257 deesterification reaction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- HNZUNIKWNYHEJJ-FMIVXFBMSA-N geranyl acetone Chemical compound CC(C)=CCC\C(C)=C\CCC(C)=O HNZUNIKWNYHEJJ-FMIVXFBMSA-N 0.000 description 1
- HNZUNIKWNYHEJJ-UHFFFAOYSA-N geranyl acetone Natural products CC(C)=CCCC(C)=CCCC(C)=O HNZUNIKWNYHEJJ-UHFFFAOYSA-N 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 239000008172 hydrogenated vegetable oil Substances 0.000 description 1
- 239000001341 hydroxy propyl starch Substances 0.000 description 1
- 235000013828 hydroxypropyl starch Nutrition 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000001525 mentha piperita l. herb oil Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- KTGKDWJBRNYLBP-UHFFFAOYSA-N n-C31-Alkan-2-one Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC(C)=O KTGKDWJBRNYLBP-UHFFFAOYSA-N 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 235000019477 peppermint oil Nutrition 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000009495 sugar coating Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000013076 target substance Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (40)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10620382A JPS58225014A (ja) | 1982-06-22 | 1982-06-22 | 免疫機能不全による疾患の予防・治療剤 |
| DE3318989A DE3318989C2 (de) | 1982-05-28 | 1983-05-25 | ß,gamma-Dihydropolyprenylalkoholderivate und diese enthaltende Arzneimittel und deren Verwendung |
| GB08314419A GB2122610B (en) | 1982-05-28 | 1983-05-25 | A polyprenyl compound and a pharmaceutical composition containing a polyprenyl compound |
| DE3348500A DE3348500C2 (de) | 1982-05-28 | 1983-05-25 | beta,gamma-Dihydropolyprenylalkoholderivat |
| DE3348493A DE3348493C2 (de) | 1982-05-28 | 1983-05-25 | Verwendung von Docosanol zur Behandlung und Prophylaxe von durch Immunmangelerscheinungen verursachten Infektionskrankheiten |
| DE3348492A DE3348492C2 (de) | 1982-05-28 | 1983-05-25 | Verwendung eines ß,gamma-Dihydropolyprenylalkoholderivats zur Prophylaxe und Therapie von durch Immunmangelerscheinungen verursachten Infektionskrankheiten |
| DK239483A DK171640B1 (da) | 1982-05-28 | 1983-05-27 | Analogifremgangsmåde til fremstilling af beta, gamma-dihydro-polyprenylalkoholderivater |
| CA000429108A CA1310660C (en) | 1982-05-28 | 1983-05-27 | B, -dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| SE8303013A SE461650B (sv) | 1982-05-28 | 1983-05-27 | B -dihydropolyprenylalkoholderivat och farmaceutisk komposition innehaallande detsamma |
| NL8301892A NL194300C (nl) | 1982-05-28 | 1983-05-27 | Farmaceutisch preparaat, dat een polyprenol als werkzaam bestanddeel bevat, alsmede voor toepassing daarin geschikte polyprenolen. |
| CH2902/83A CH654823A5 (fr) | 1982-05-28 | 1983-05-27 | Derives de l'alcool beta, gamma-dihydropolyprenylique et compositions pharmaceutiques contenant un compose polyprenylique. |
| ES522789A ES8406992A1 (es) | 1982-05-28 | 1983-05-27 | Un derivado de un alcohol b,v-dihidropoliprenilico. |
| AT0197283A AT389871B (de) | 1982-05-28 | 1983-05-30 | Verfahren zur herstellung von beta, gamma -dihydropolyprenylalkoholderivaten |
| FR838308941A FR2527597B1 (fr) | 1982-05-28 | 1983-05-30 | Derives d'alcool b,g-dihydropolyprenylique et composition pharmaceutique contenant un compose polyprenylique |
| IT21364/83A IT1164256B (it) | 1982-05-28 | 1983-05-30 | Derivati di beta, alfa-diidropoliprenil alcool e composizione farmaceutica contenente un composto di poliprenile |
| FR8317176A FR2532847B1 (fr) | 1982-05-28 | 1983-10-27 | Composition pharmaceutique comprenant a titre de principe actif le 3,7,11,15-tetramethylhexadeca-1-ene-3-ol |
| FR8317169A FR2532843A1 (fr) | 1982-05-28 | 1983-10-27 | Composition pharmaceutique comprenant a titre de principe actif le phytol ou l'isophytol |
| FR8317173A FR2532845B1 (fr) | 1982-05-28 | 1983-10-27 | Composition pharmaceutique comprenant a titre de principe actif le docosanol |
| FR8317175A FR2532846B1 (fr) | 1982-05-28 | 1983-10-27 | Composition pharmaceutique comprenant a titre de principe actif le 3,7,11,15 - tetramethyl -1,6,10,14-hexadecatetraene-3-ol |
| FR8317171A FR2532844B1 (fr) | 1982-05-28 | 1983-10-27 | Composition pharmaceutique contenant un compose polyprenylique |
| FR8317170A FR2532848B1 (fr) | 1982-05-28 | 1983-10-27 | Composition pharmaceutique contenant un derive polyprenylique |
| ES529754A ES8507444A1 (es) | 1982-05-28 | 1984-02-15 | Un procedimiento para la preparacion de un derivado de un alcohol , -dihidropoliprenilico |
| ES529753A ES8506567A1 (es) | 1982-05-28 | 1984-02-15 | Un procedimiento para la preparacion de un derivado de un alcohol , -dihidropoliprenilico |
| GB08508220A GB2159713A (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| GB08508215A GB2159709B (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| GB08508216A GB2159055B (en) | 1982-05-28 | 1985-03-29 | Pharmaceutical compositions of 3,7,11,15-tetra-methylhexadec-1-en-3-ol |
| GB08508217A GB2159710B (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| GB08508214A GB2159054B (en) | 1982-05-28 | 1985-03-29 | Pharmaceutical compositions of polyprenyl alcohols |
| GB08508219A GB2159712B (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| GB08508218A GB2159711B (en) | 1982-05-28 | 1985-03-29 | Containing a polyprenyl compound |
| US06/760,221 US4624966A (en) | 1982-05-28 | 1985-07-29 | β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| FR858513026A FR2569108B1 (fr) | 1982-05-28 | 1985-09-02 | Composition pharmaceutique contenant un compose polyprenylique |
| SE8801515A SE502924C2 (sv) | 1982-05-28 | 1988-04-22 | Farmaceutisk komposition innehållande en verksam mängd av 3,7,11,15-tetrametyl-hexadeka-1-en-3-ol eller 3,7,11,15- tetrametyl-1,6,10,14-hexadekatetraen-3-ol |
| SE8801514A SE502923C2 (sv) | 1982-05-28 | 1988-04-22 | Användning av en polyprenylförening för framställning av protylaktiskt/terapeutiskt medel för humana och animala sjukdomar beroende på bristfälligt immunförsvar |
| SE8801513A SE502922C2 (sv) | 1982-05-28 | 1988-04-22 | Användning av en polyprenylförening för framställning av profylaktiskt/terapeutiskt medel för humana och animala sjukdomar beroende på bristfälligt immunförsvar |
| US08/011,197 US5280048A (en) | 1982-05-28 | 1993-01-29 | β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| US08/584,145 US6111131A (en) | 1982-05-28 | 1996-01-11 | Beta, gamma-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| US08/599,944 US5658958A (en) | 1982-05-28 | 1996-02-14 | β, γ-dihydropolyprenyl alcohol derivatives effective at mitigating stress in animals |
| US08/601,489 US6288128B1 (en) | 1982-05-28 | 1996-02-14 | β,γ-dihydropolyprenyl alcohol derivatives and pharmaceutical composition containing a polyprenyl compound |
| NL9900009A NL9900009A (nl) | 1982-05-28 | 2000-12-05 | Beta, gamma-dihydropolyprenylalcoholderivaten en farmaceutisch preparaat, dat een polyprenylverbinding bevat. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP10620382A JPS58225014A (ja) | 1982-06-22 | 1982-06-22 | 免疫機能不全による疾患の予防・治療剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS58225014A JPS58225014A (ja) | 1983-12-27 |
| JPH026328B2 true JPH026328B2 (enrdf_load_stackoverflow) | 1990-02-08 |
Family
ID=14427601
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10620382A Granted JPS58225014A (ja) | 1982-05-28 | 1982-06-22 | 免疫機能不全による疾患の予防・治療剤 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS58225014A (enrdf_load_stackoverflow) |
-
1982
- 1982-06-22 JP JP10620382A patent/JPS58225014A/ja active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS58225014A (ja) | 1983-12-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE3318989C2 (de) | ß,gamma-Dihydropolyprenylalkoholderivate und diese enthaltende Arzneimittel und deren Verwendung | |
| JPS58134031A (ja) | 多発性硬化症処置におけるジヒドロシクロスポリンｄ | |
| EP0629400B1 (en) | Idebenone compositions for treating Alzheimer's disease | |
| EP0774255A1 (en) | Use of ursolic acid for the manufacture of a medicament for suppressing metastasis | |
| US4623641A (en) | Method of treating ulcers and erosions in the gastrointestinal system using PGI2 -methyl ester-beta cyclodextrin inclusion complexes | |
| JPH026328B2 (enrdf_load_stackoverflow) | ||
| EP0938900B1 (en) | Preventives/remedies for stomatitis | |
| JPH026326B2 (enrdf_load_stackoverflow) | ||
| WO1992004028A1 (fr) | Potentialisateur d'effets antineoplasique et agent antineoplasique | |
| JPH026327B2 (enrdf_load_stackoverflow) | ||
| JPS6210013A (ja) | 胃炎治療・予防剤 | |
| JPH07506568A (ja) | 糖尿病治療のための既存の薬剤の使用 | |
| JPH0325405B2 (enrdf_load_stackoverflow) | ||
| US3852454A (en) | Treatment of rheumatoid arthritis | |
| US4447437A (en) | Pharmaceutical composition and method for treatment of peptic ulcer | |
| JPH02172920A (ja) | 抗潰瘍剤 | |
| CN107397810B (zh) | 基于铁的氢氧化物－桃胶的磷结合剂、其制备方法及其应用 | |
| JPS5938206B2 (ja) | 補酵素ｑを主成分とする気管支喘息治療剤 | |
| JPH0623108B2 (ja) | 腫瘍形成抑制用組成物 | |
| JPH0349891B2 (enrdf_load_stackoverflow) | ||
| JPH02330B2 (enrdf_load_stackoverflow) | ||
| JPH0120128B2 (enrdf_load_stackoverflow) | ||
| CA2259997C (en) | Remedies and preventives for stomatitis | |
| JPH06279445A (ja) | ガン転移抑制剤 | |
| JP2579486B2 (ja) | 中枢神経抑制剤 |